however, no impact on other pro-inflammatory markers, including C-reactive protein (CRP), IL-6, IL-17, or immunoglobulin antibodies, was observed
The exact cutoff and plan are set by your prescriber and the product labeling
This development may broaden access to pharmacologic weight-management options and could act as an accelerator within current obesity-care pathways
GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have become household names, and the weight loss results can be remarkable
Immediate consultation is warranted if you are considering extending your dosing interval to every other week, as this represents a significant deviation from FDA-approved prescribing information
Poor Appetite or Difficulty Eating Enough: The goal is not to stop eating but to reduce excessive hunger and calories